Oragenics, Inc. develops antibiotics for infectious diseases in the United States. NT-CoV2-1,an intranasal vaccine candidate provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.
